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1. Introduction  
Tuberculosis (TB) remains one of the most serious infectious diseases in the world requiring 
new and more effective diagnostics and treatments (World Health Organization [WHO], 
2010). Several approaches have been developed to improve TB diagnostics, reducing the 
time from weeks to a few days that still require demanding expertise technical personal for 
labor intensive and expensive methods, which hamper application in resource-poor 
countries where the main TB epidemic is observed. Nanotechnology has triggered the 
development of new and cheaper approaches for biomolecular recognition that may 
circumvent the current limitations of conventional molecular diagnostic methods used in 
the global fight against TB. This new era of molecular nanodiagnostics may provide a rapid 
and sensitive detection of the main TB etiologic agent in humans, i.e. Mycobacterium 
tuberculosis.  
Nanodiagnostics can be defined as the use of nano-sized materials, devices or systems for 
diagnostics purposes. Biological tests measuring the presence or activity of selected analytes 
become quicker, more sensitive and more flexible when nanoscale particles are put to work 
as tags or labels, with numerous advantages over more traditional procedures, for example 
fluorescence and chemiluminescence technology. Here we will provide a closer look into 
nanodiagnostics systems developed for TB diagnostics and/or M. tuberculosis detection and 
characterization, such as nanoparticle-based systems (e.g. gold, silver, silica and quantum 
dots) and nanocantilevers. These techniques are already showing to be more sensitive and 
specific than conventional commercial molecular diagnostics methodologies although many 
aspects of nanodiagnostics for TB still need further evaluation and validation. Current 
advances in nanofabrication may enable the construction of cheap and full-automated 
devices, extending the limits of current molecular diagnostics and enable point- of-care 
diagnostics.  
2. Tuberculosis  
Tuberculosis is caused by M. tuberculosis, a member of the Mycobacterium tuberculosis 
complex (MTBC) and, according to the most current statistics of the World Health 
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Organization, remains one of the most serious infectious diseases in the world, being 
responsible for 1.7 million deaths and 9.4 million new cases in 2009 alone (WHO, 2010). The 
emergence of multidrug-resistant TB also represents a serious threat to the TB control and 
an increasing public health problem (Deun et al., 2010), leading to a global need for rapid 
drug susceptibility testing. Single nucleotide sequence variations (mutations and/or 
polymorphisms) within M. tuberculosis genome have been associated with antibiotic 
resistance for all first-line drugs (isoniazid, rifampin, pyrazinamide, ethambutol, and 
streptomycin), and for several second-line and newer drugs (ethionamide, fluoroquinolones, 
macrolides, and nitroimidazopyrans), making these sequences ideal targets for the 
development of molecular drug susceptibility testing (Abebe et al., 2011; Miller et al., 1994; 
Musser, 1995; Soini & Musser, 2001; Telenti et al., 1993).  
The mainstay for TB diagnostics in endemic developing countries is sputum smear 
microscopy (Perkins, 2009). However, the sensitivity of this technology is low as it can only 
detect roughly half of all active cases of tuberculosis when properly used – in people with 
co-infections and in children the sensitivity is even lower. Moreover, though routinely 
described as a simple technology, microscopy is actually complex, and highly dependent on 
the training and diligence of the technician, requiring multiple examinations which may 
take weeks to complete, with the consequence that many patients drop out during the 
diagnostic process. Several diagnostic approaches have brought incremental improvements 
for the direct detection, species identification and drug susceptibility testing of mycobacteria 
that are capable of reducing the laboratorial time from weeks to a few days (Barnard et al., 
2008; D'Amato et al., 1995; De Beenhouwer et al., 1995; Griffith et al., 2007; Hillemann et al., 
2005; Hirano et al., 1999; Moore et al., 2006; Park et al., 2002; Rossau et al., 1997; Sharma et 
al., 2003; Traore et al., 2000). Most of these approaches for direct detection of TB and drug 
susceptibility from clinical specimens, including several commercial tests, rely on complex 
and expensive DNA amplification based procedures (e.g. PCR), whereas the need is for 
affordable, simple and high-throughput systems with the possibility to use small amounts 
of sample (Cheng et al., 2005; Das et al., 2010; Shamputa et al., 2004; Watterson et al., 1998). 
These molecular recognition assays still need to make the way to widespread utilization in 
some technological advanced countries, which will definitely delay the required validation 
and setup for simplified platforms for general use at more remote and less equipped areas. 
Some of the diagnostic tools expected to be introduced into control programs will be 
incremental improvements on existing technologies while others will be radically new. The 
speed and extent of adoption of new technologies will depend on the balance between the 
benefits they bring and the degree of disruption their implementation causes. For instance, a 
simplified microscopy method may see greater adoption than a novel alternative that 
necessitates changes in the way testing or case notification are carried out. On the other 
hand, a new method that rapidly identifies all smear-positive and many smear-negative 
cases might, if suitably robust and specific, see widespread use and could substantially 
replace microscopy. Point-of-care diagnosis is instrumental to TB control because, despite 
having the necessary treatment, strategies in some regions are rather ineffective (see South 
Africa as an example). Identifying new cases very quickly and getting patients immediately 
on to treatment are crucial in addressing this pandemic. New diagnostic tools for drug 
resistant TB (TB that is resistant to drugs – multi-drug resistant TB, MDR-TB) are urgently 
needed for reducing diagnostic time from months to days.  
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Several new technologies are under development, which will enable the presumptive 
diagnosis of MDR-TB in just one to two days, compared with two or more months when 
using conventional culture and drug susceptibility tests. Rapid diagnosis of MDR-TB will 
have several benefits: earlier treatment of patients, reduction of time spent on inappropriate 
and ineffective treatment (thereby promoting the development of further drug resistance), 
and reduction of MDR-TB spreading in congregate settings. 
3. Nanodiagnostics for TB  
Nanotechnology introduced new paradigms for molecular diagnostics – nanodiagnostics, 
where the increased sensitivity, specificity, speed and reduced cost constitutes an appealing 
alternative to conventional techniques (Azzazy et al., 2006). Because we are dealing with 
nanometer sized objects and/or nanometer scale, bulk matter physics does not apply and 
amazing and extraordinary new properties arise. This interesting field relies on the 
knowledge and technological developments emerging from transdisciplinary research 
efforts that bring together a plethora of expertise from areas as diverse as Materials Science, 
Physics, Biology and Biotechnology, Chemistry and Medicine. From the intersection of these 
complementarities new and radical approaches can be explored towards application in 
platforms for biomolecular recognition (e.g. nucleic acids, antibodies, proteins, etc.) that can 
be miniaturized for point of care utilization and/or for enhanced portability for small 
laboratory settings in remote areas without the standard access to conventional laboratory 
equipment and apparatus. Nanodiagnostics have redefined the standards for molecular 
diagnostics, triggering the development of new approaches in biomolecular recognition and 
analytical systems, where the most promising approaches include nanoparticles (NPs), 
nanotubes, nanopores and nanocantilever technologies (Baptista et al., 2008; Branton et al., 
2008; Jain, 2007; Rosi & Mirkin, 2005; Wang et al., 2009). Their potential arises from 
recognition events occurring at one-to-one interactions between analytes and signal-
generating nanostructures, allowing for an increased sensitivity and specificity at lower 
costs. 
Different nanodiagnostics systems have been developed for the molecular diagnostics of TB. 
Despite the wide range of nanoscale systems being used for biomolecular assays in general 
(e.g. electromechanical, electrochemical) (Azzazy et al., 2006; Das et al., 2010; Jain, 2007), 
nanoparticle based systems, such as gold, silver, silica and quantum dots (QDs), have been 
the most widely used for TB diagnostics due to their unique physicochemical properties, 
that offer greater sensitivity than conventional reporter molecules and can be easily tuned 
and functionalized by simple chemistry modulation and derivatization (Azzazy, 2009). 
Table 1 summarizes existing nanotechnology based systems applied to TB diagnostics. 
3.1 Nanoparticles 
Nanoparticles are typically in the size range of 1–100 nm and can have different shapes and 
compositions (Liu, 2006). They are structurally robust and have very specific size dependent 
properties that differ considerably from those observed on microparticles or bulk materials. 
Depending on their size and composition they exhibit peculiar properties, such as quantum 
confinement in semiconductor nanocrystals, surface plasmon resonance (SPR) in some metal 
NPs and superparamagnetism in magnetic materials (Vollath, 2008). They also provide large 
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Detection relies on the 
evaluation of SPR 
change upon 
aggregation and the 
concomitant colorimetric 
changes that can be 
assessed by the naked 
eye. 
> Specific detection of M 
tuberculosis complex, M. avium
complex, M. avium subsp. 
paratuberculosis, M. bovis and 
M. tuberculosis. 
> Detection of rpoB mutations 
associated with drug 
resistance. 
Baptista  
et al., 2006;  
Costa  
et al., 2010;  
Liandris  
et al., 2009;  
Silva  
et al., 2008, 2010;  
Soo et al., 2009; 
Veigas  
et al., 2010 
Magnetic NPs 
Detection by 
measurement of  
the spin-spin relaxation 
time. Minimal sample 
preparation needed, 
without the need  
for sample amplification.
 
> High sensitive detection of 
bacillus Calmette-Guérin. 
Kaittanis  
et al., 2007;  












Optimal for  
multiplex assays. 
 
> Conjugation of 
streptavidin-coated QDs 
with specific bacteriophage. 
> Integration with magnetic 
NPs for the detection of M. 
tuberculosis and M. avium 
subsp. paratuberculosis. 
Rotem  
et al., 2006;  
Gazouli  
et al., 2010 
Silica NPs 
Fluorescence detection 
of NPs with large 
quantities of fluorophore
molecules inside a 
polymer or silica matrix.
Easy conjugation with 
several biomolecules 
and fluorophore 
making. Ideal for 
multiplex assays. 
> Detection of M. tuberculosis 
by combining luminescent 
NPs and indirect 
immunofluorescence 
microscopy. 
> Improved two-color flow-
cytometry assay by a 
combination of the 
bioconjugated  
fluorescent silica  
NPs and SYBR  
Green I to avoid  
false positives. 
Qin  
et al., 2007, 2008 
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resonance biosensor for 
rapid, quantitative, and 
multiplexed detection of 
biological targets. 
Reduced cost of the 
automated sensitive 





> Specific detection of M. 
tuberculosis by nanostructured 
zinc oxide (nsZnO) films. 
> Amorphous/ 
nanocrystalline  
biosensor integrated into  
an optoelectronic  
platform for the  
specific identification of  
M. tuberculosis complex 
members. 
 
Das et al., 2010; 
Lee et al., 2010; 
Wang et al., 1997;  
Prabhakar  
et al., 2008;  
Table 1. Nanotechnology systems for TB diagnostics 
surface to volume ratio with the same size range of biomolecules and cellular organelles, 
allowing a nearly one-on-one interaction between the NP and the biomolecule of interest 
(Azzazy et al., 2006, 2007; Jain, 2005) and making them of high potential for use in in vitro 
diagnostics. The most promising NPs already applied to TB diagnostics are gold, magnetic 
and silica NPs, and QDs. Size-dependent properties of the NPs also enable modification of 
the surface for conjugation with various biomolecules allowing for a wide range of bioassay 
applications (Salata, 2004).  
3.1.1 Noble metal nanoparticles 
Nobel metal NPs have attracted considerable attention in molecular diagnostic applications 
due to their simplicity and versatility, becoming a critical component in the development of 
nanotechnology-based detection of pathogens (Liu, 2006). Gold NPs (AuNPs), in particular, 
have been extensively used due to their unique optical properties with their typical bright 
red color in colloidal solutions associated with a well-defined SPR band in the visible region 
of the spectrum (Halfpenny & Wright, 2010). This SPR is originated from the collective 
oscillation of conduction band electrons at the NPs’ surface induced by the interacting 
electromagnetic radiation of light. The SPR band is weakly dependent on size of the NP and 
refractive index of the surrounding media, but changes considerably with the composition, 
shape and inter-particle distance (Johnson et al., 2007). In the latter case, the aggregation of 
AuNPs leads to a pronounced color transition from red to blue due to plasmon coupling 
between NPs (Jain, 2007). Another remarkable property of AuNPs is the easiness of chemical 
functionalization via the use of thiol-ligands (e.g. thiol-modified oligonucleotides, 
antibodies or other biomolecules) that form quasi-covalent bonds with the NP’s gold 
surface, rendering gold nanoprobes for specific target recognition (Daniel & Astruc, 2004).  
Most AuNPs based methods rely on the colorimetric changes of the colloidal solution upon 
aggregation either mediated by a change to the dielectric medium or by recognition of a 
specific target. The design of these systems is centered in the ability of complementary 
targets to balance and control inter-particle attractive and repulsive forces, which determine 
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whether AuNPs are stabilized or aggregated and, consequently, the SPR band and color of 
the solution remains unaltered or changes, respectively. For example, a specific 
complementary target can hybridize to the gold nanoprobes and promote an inter-particle 
cross-linking aggregation (e.g. when using two nanoprobes with contiguous target 
recognition) or stabilize the nanoprobes against the changes of the dielectric medium, which 
otherwise would induce a non-cross-linking aggregation of the nanoprobes in the absence of 
a complementary target (e.g. exploring the differential salt induced non-cross-linking 
aggregation of the nanoprobes) (Baptista et al., 2005).  
The first application of AuNPs for the molecular diagnostics of M. tuberculosis was 
introduced by Baptista et al. (Baptista et al., 2006). The method consists in differential 
stabilization of gold nanoprobes in the presence of different DNA targets. The presence of a 
complementary target prevents nanoprobe aggregation and the solution remains red, while 
non-complementary/mismatched targets or their absence do not prevent gold nanoprobe 
aggregation, resulting in a visible change of color from red to blue. The gold nanoprobes 
were functionalized with thiol-modified oligonucleotides harboring a sequence derived 
from the M. tuberculosis RNA polymerase β-subunit gene sequence suitable for mycobacteria 
identification. The methodology was tested in clinical samples demonstrating high 
efficiency when combined with an initial round of PCR for target amplification (Baptista et 
al., 2006) – see Figure 1. 
The attained results have shown a 100% concordance with the available commercial 
molecular TB diagnostics test INNO-LiPA Rif.TB. Following optimization towards detection 
of single base mismatches (Doria et al., 2010), this strategy was applied to the rapid 
detection of MTBC strains and simultaneous characterization of the presence of mutations 
associated with rifampicin resistance (Veigas et al., 2010).  This low-complexity assay 
enabled the detection of mutations D516V and S531L from MTBC clinical specimens with 
remarkable sensitivity in just a few hours. Based on the molecular signatures of MTBC 
members and the most common mutations associated with RIF resistance in M. tuberculosis, 
a two-step approach based on the PCR amplification of a fragment of rpoB gene and 
subsequent hybridization with specific nanoprobes, namely a probe for the rpoB locus 
shared by all the members of the MTBC and a probe specific to MTBC members, was 
developed. Three additional sets of probes specific for the most common point mutations 
associated with RIF resistance (D516V; H526D; S531L) were also designed and synthesized. 
Each set composed of two probes: one complementary to the wild-type sequence and the 
other complementary to the mutation. A limit of detection could be set at 75 nM, however, 
for robust single base mismatch determination, 117 nM of DNA target were used per assay. 
This non-cross-linking approach correctly detected the presence of DNA from members of 
the MTBC in 83.3% of all samples, when compared to the INNO-LiPA Rif.TB assay. By 
means of a set of two probes for each mutation associated to RIF resistance to be screened 
(mutations in codons 516, 526 and 531 of the rpoB gene), it was possible to correctly score 
the presence of at least one of the mutations in 81% of all samples also screened via the 
INNO-LiPA Rif.TB assay. Following PCR amplification, the method takes only 90 min to 
yield a colorimetric result which, through the use of a suitable photodetector (e.g. 
UV/visible spectrophotometer, microplate reader, etc.), may be used in medium throughput 
analysis at a peripheral laboratory or point-of-care. Fast and reliable identification of MTBC 
members and mutations within the rpoB gene is of great advantage as it is a secondary 
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marker for isoniazid resistance allowing to predict, with a high degree of confidence, 
whether the strain is indeed a multidrug-resistant TB (Hillemann et al., 2005). 
 
Fig. 1. Non-cross-linking detection of MTBC members. A DNA sample is extracted from a 
patient and amplified by a first round PCR. The resulting PCR product is characterized 
using gold nanoprobes and following a non-cross-linking approach that consists of a visual 
comparison between solutions before and after salt induced nanoprobe aggregation: ’Blank’, 
nanoprobe alone; ‘MycoNEG’, nanoprobe in the presence of a non-complementary DNA 
sequence; and ‘MycoPOS’, nanoprobe in the presence of a complementary DNA sequence. 
Optimization of the above strategy allowed detection and identification of members of the 
MTBC at the species level. Three different nanoprobes based on the gyrB locus, allowed the 
specific identification of MTBC, M. bovis and M. tuberculosis (Costa et al., 2010). Based on the 
conserved gyrB gene sequence between species from the MTBC, a set of primers was used to 
PCR amplify a specific 1020 bp fragment of the gene from MTBC species only. In silico 
alignment of the gyrB gene sequences showed three regions that allowed discrimination 
between MTBC members. As proof-of-concept, one probe was designed to identify this 
genomic region shared by all the members of the MTBC, and two probes were designed to 
specifically identify M. tuberculosis and M. bovis, respectively. The MTBC probe positively 
identified the members of the MTBC used in the assay, while clearly discriminating the non-
members. The M. tuberculosis and M. bovis probes unequivocally identified the respective 
species. Also, a blind assay using mycobacteria strains isolated from fifteen different clinical 
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samples showed 100% concordance with the results attained by the gyrB-PCR-RFLP 
method.  
Towards a point-of-care application, Baptista and co-workers further integrated the non-
cross-linking nanoprobe-based method in an innovative optoelectronic platform that allows 
an analytical measurement of the colorimetric changes, hence to detect a target without the 
need of experienced personnel. The device integrates an amorphous/nanocrystalline 
biosensor and a light emission source with the non-cross-linking method for specific DNA 
detection. This low cost, fast and simple optoelectronic platform was optimized for the 
specific identification of MTBC members and the consequent improvement of the 
laboratorial diagnostics algorithms of TB (Bernacka-Wojcik, et al., 2010; Silva et al., 2008, 
2010). The integration of these technologies together with the possibility of miniaturization 
are of utmost importance for the development of an integrated biosensor suitable for 
peripheral laboratories and/or point-of-care diagnostics, providing a new tool in the fight 
against TB.  
Recently, Liandris et al. have developed a non-cross-linking approach to the detection of TB 
without the need of target amplification (Liandris et al., 2009). The method relied on the 
same non-cross-linking hybridization approach of Baptista and co-workers, whereas the 
aggregation of the gold nanoprobes was induced by an increasing acid concentration 
instead of salt. The detection is based on the fact that double and single-stranded 
oligonucleotides have different electrostatic properties. After hybridization, single-stranded 
DNA becomes double-stranded DNA. As a result, the double-stranded DNA cannot uncoil 
sufficiently like the single-stranded DNA to expose its bases toward the gold nanoprobe. 
Therefore, the nanoprobe undergoes aggregation in an acidic environment. Liandris and 
coworkers designed an array of gold nanoprobes to collectively detect the main 
mycobacterial pathogens in clinical samples, namely MTBC, M. avium complex and M. 
avium subsp. paratuberculosis. A nanoprobe harboring 20 nucleotides was designed to harbor 
a conserved genus region sequence of 16s–23s ITS DNA of the most common mycobacterial 
pathogens. In order to obtain an indication of the method's performance on clinical samples, 
the assay was tested for the detection of M. avium subsp. paratuberculosis DNA in feces. For 
this purpose, 12 fecal samples were collected from an equal number of goats from a herd 
with a well-established record of M. avium subsp. paratuberculosis and the results were 
compared to those obtained by a real-time PCR assay. The quantification was performed 
using M. avium subsp. paratuberculosis DNA of known concentration, and the standard curve 
as obtained by real-time PCR. The evaluation of the specificity and repeatability of this non-
cross-linking approach indicated a reliable and highly specific detection of a broad spectrum 
of mycobacteria without cross reactions with related bacteria (the concordance of the two 
methods with connection to real-time PCR positive and negative sample was defined 
respectively as 87.5% and 100%). Moreover, the methodology demonstrated to be highly 
sensitive, where even the lowest concentration of the targeted sequence was easily detected 
by simple visual observation of the test and the control tubes (Liandris et al., 2009). 
Following a cross-linking approach, Soo et al. designed a set of gold nanoprobes to 
specifically hybridize with target DNAs of MTBC and M. tuberculosis strains (Soo et al., 
2009). The nanoprobes were oriented in a tail-to-tail arrangement, one probe functionalized 
via a thiol moiety located at the 5’end of the sequence and other at 3’ end, with both 
sequences being contiguous to each other. This way the hybridization of the nanoprobes 
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with the complementary target resulted in the formation of a polymeric cross-linked 
network, bringing the AuNPs close enough to induce a color change from red to blue 
(Beermann et al., 2007; Li et al., 2006; Liandris et al., 2009; Storhoff et al., 2005).  The efficacy 
of such cross-linking assay was evaluated by analyzing sputum specimens. Results were 
compared with traditional culture and biochemical identification methods together with 
patients clinical assessments. The detection limit of this assay was measured using IS6110 
DNA amplified from M. tuberculosis H37Rv chromosome. This methodology was able to 
detect as low as 0.5 pmol of DNA target within two hours. The assay comprises two main 
steps, namely, the target DNA amplification by single or nested PCR, followed by 
nanoprobe detection. The gold nanoprobes are added to the heat denatured PCR products, 
and incubated at 55ºC for DNA hybridization with increased stringency. In the presence of 
complementary DNA the nanoprobes aggregated upon hybridization to the target, resulting 
in decrease in absorbance of the solution at 525 nm. On the other hand, the color and 
absorbance pattern did not change when specific complementary target DNAs were absent 
in the solution. The methodology was evaluated by directly and simultaneously detecting 
MTBC and M. tuberculosis from 600 clinical strains and comparing the results with those 
from conventional culture methods and biochemical identification in combination with 
clinical assessment. The assay presented 96.6% sensitivity and 98.9% specificity towards 
detection of MTBC, and 94.7% sensitivity and 99.6% specificity for detection of M. 
tuberculosis.  
3.1.2 Magnetic nanoparticles 
Magnetic properties are largely dependent on the composition and molecular structure of 
the NPs (Lu et al., 2007). Different materials can exhibit diamagnetic, paramagnetic or 
ferromagnetic behavior (Sato et al., 2003). In most cases, the particles range from 1 to 100 nm 
in size and may display supermagnetism when the thermal energy is enough to change the 
direction of magnetization of the NPs (Neubergera et al., 2005). Superparamagnetic NPs 
made of magnetic materials (e.g. iron, nickel, cobalt, or alloys of magnetic metals) are 
preferred for biomedical applications, due to the fact that they behave non-magnetically 
when they are not under the influence of an external magnetic field, thus preventing 
undesired self-magnetic agglomeration. In the presence of an external magnetic field 
gradient, the large magnetic moments of all the atoms align with the field and the 
superparamagnetic NPs can be manipulated to interact with different biomolecules (Jain, 
2007). Removing the external magnetic field causes the NPs to lose their alignment with the 
field and relax into random directions of magnetization. To make the superparamagnetic 
NPs biocompatible, they are coated with a material such as silica or polyethylene glycol, and 
then functionalized with the relevant targeting biomolecule for the desired application, such 
as antibodies, proteins or oligonucleotides (Jain, 2005). As an example, superparamagnetic 
NPs have been used in the development of a magnetic immunoassay. The presence of a 
target analyte allows the superparamagnetic NPs to bind to a magnetic sensor in a sandwich 
conformation, which creates a local magnetic field that is detected by the sensor once an 
applied external field is used to induce a magnetic moment in the superparamagnetic NPs, 
(Sato et al., 2003).  
Kaitanis and coworkers designed superparamagnetic iron oxide nanoprobes coupled with a 
magnetic relaxation methodology to detect Mycobacterium avium spp. paratuberculosis, in 
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milk and blood (Kaittanis et al., 2007). The methodology could quickly quantify the bacterial 
target with high sensitivity, and was not susceptible to interferences caused by other 
bacteria. The principle underlying the detection by these nanosensors is their ability to 
change between disperse and clustered (or assembled) state upon target interaction, with a 
concomitant change in the spin-spin relaxation time of the solution’s water protons. This 
approach, apart from sensitive and fast, is independent of the sample’s optical properties 
and requires minimum sample preparation. More recently, Lee et al. developed a very 
similar methodology where bacteria were targeted by highly magnetic NPs with a large Fe 
core and a thin ferrite shell NPs, concentrated into a microfluidic chamber, and detected by 
nuclear magnetic resonance (Lee et al., 2009). The clinical utility of this diagnostic platform 
was evaluated by detecting TB using the bacillus Calmette-Guérin (BCG) as a surrogate for 
M. tuberculosis. Following liquefaction, the samples were subjected to standard TB 
diagnostic tests, namely culture and acid-fast bacilli smear microscopy, to be compared with 
the magnetic NPs-based nuclear magnetic resonance measurements. This methodology 
shown similar results to those attained with the standard culture-based methods (detection 
limit of ~20 colony forming units) with the advantage to be less prone to human error and 
less labor-intensive. The nuclear magnetic resonance-based detection was much faster (< 30 
min) and performed on a single microfluidic chip, markedly contrasting with the culture-
based test that was time-consuming (> 2 weeks) and facility-dependent (e.g. incubators).  
Both these methodologies are in their first stages of development and present great 
advantages over current techniques such as speed, easiness of procedure and minimum 
sample preparation. 
3.1.3 Quantum dots 
Quantum dots are inorganic fluorophores with size-dependent optical properties, exhibiting 
strong light absorbance, bright and narrow symmetric emission bands and high photo 
stability, due to three-dimensional quantum confinement effects (Chan et al., 2002; 
Yezhelyev et al., 2006). The size and composition of QDs determine their emission 
wavelength and color (Coto-García et al., 2011; Michalet et al., 2005; Sukhanova & Nabiev, 
2008). Moreover, the QDs can maintain these properties upon conjugation to biomolecules 
(Alivisatos et al., 2005; Fortina et al., 2005; Salata, 2004) making them preferred fluorescent 
probes for imaging applications (Halfpenny & Wright, 2010). The fact that QDs do not 
depend on the presence of a variety of different fluorescence dyes also allows their 
application for multiplexing analysis (Azzazy & Mansour, 2009). Although QDs are 
typically insoluble in water, they can be made biocompatible by several strategies including 
silanization and coating with a polymer shell, thus enabling their utilization in biological 
systems. Target specificity is achieved by conjugating them to a variety of biomolecules, 
such as antibodies, streptavidin and oligonucleotides, enabling their application in 
conventional molecular biological methodologies, such as fluorescent in situ hybridization 
(FISH), immunological assays or northern/southern/western blots (Michalet et al., 2005). In 
fact, QDs have already been used in a number of biological applications including studies of 
protein trafficking, DNA detection and dynamic studies of cell mobility (Zrazhevskiy et al., 
2010). Rotem and coworkers reported the use of QDs for the detection of pathogenic bacteria 
combining in vivo biotinylation of engineered host-specific bacteriophage with the 
conjugation of the phage to streptavidin-coated fluorescent QDs (Rotem et al., 2006). 
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Although the proof of concept only used a single phage–host system, the method may be 
expanded for the detection of multiple bacterial strains by their specific phages. This 
concept could be applied to any slow growing pathogen, such as M. tuberculosis for TB 
diagnostics. 
Only recently QDs have been used for the detection and imaging of respiratory pathogens 
and, in particular, for TB diagnostics. Gazouli and coworkers developed and evaluated a 
detection assay for specific DNA sequences combining fluorescent semiconductor QDs with 
magnetic beads allowing for a fast identification of two members of the Mycobacterium genus 
(M. tuberculosis and M. avium subsp. paratuberculosis) without the need for DNA 
amplification (Gazouli et al., 2010). The assay involves two biotinylated oligonucleotide 
probes to recognize and detect specific complementary mycobacterial target DNA through a 
sandwich like hybridization. Five 30-bp-long genus-specific probes were designed for the 
detection of Mycobacterium based on the 23S rRNA gene, which is highly conserved among 
the mycobacterial species. For the detection of M. tuberculosis and M. avium subsp. 
paratuberculosis, 2 sets of five 30-bp-long probes were designed based on IS6110 and IS900, 
respectively. Cadmium selenite QDs conjugated with streptavidin and species-specific 
probes were used to produce a fluorescent signal, while the magnetic beads conjugated with 
streptavidin and genus-specific probes were used to isolate and concentrate the DNA 
targets. The minimum detection limit of the assay was defined to be 12.5 ng of DNA diluted 
in a sample volume of 20 μl. In order to obtain an indication of the method’s performance 
with clinical samples, the system was compared with conventional diagnostics 
methodologies, namely Ziehl-Neelsen staining and real-time PCR. Additionally, to assess 
the performance of the assay with clinical material, DNA isolated from bronchoalveolar 
lavage samples, formalin-fixed paraffin-embedded tissues or feces was used for the 
detection of M. tuberculosis and M. avium subsp. paratuberculosis. With regard to M. 
tuberculosis, the assessment relied on DNA isolated from bronchoalveolar lavage samples 
from 48 patients with clinical tuberculosis and 12 bronchoalveolar lavage samples from 
healthy individuals, both confirmed by culture and real-time PCR, with the exception of a 
bronchoalveolar lavage sample that reacted negatively by the latter method. The overall 
concordance of this assay was 84.61% and 100% with regard to positive and negative results, 
respectively. This approach of capturing and detection in two steps by different building 
blocks minimizes false-positives associated with low specificity. Given that the capture and 
detection probes of the QD assay are complementary to different genes of the mycobacterial 
genome, the chances of false-negative results due to DNA fragmentation are inevitably 
increased. Nonetheless, this weakness can be circumvented by the use of a different set of 
DNA probes that anneal closer to each other, allowing an assessment that minimizes false-
positive results associated with low specificity (Gazouli et al., 2010). Additionally, the 
method avoids the drawback of PCR-based diagnostic assays that are prone to false-
negative results generated by inhibitors commonly found in clinical samples such as feces.  
3.1.4 Silica nanoparticles 
Fluorescence-based detection techniques have been extensively used in both biological 
research and clinical diagnostics, due to the extremely high sensitivity. Dye-doped silica 
NPs contain large quantities of dye (fluorophore) molecules inside a polymer or silica 
matrix, amplifying the fluorescence of each interaction event. This signal enhancement 
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facilitates ultrasensitive analyte determination otherwise undetectable with conventional 
fluorescence labeling techniques. Furthermore, the polymer and silica matrix serves as a 
protective shell, reducing photo-bleaching (Zhao et al., 2007) and allows a high versatility 
towards different surface modification protocols (Tan et al., 2004). These silica NPs are also 
more hydrophilic, biocompatible and not subject to microbial degradation, swelling or 
porosity changes with varying pH (Jain et al., 1998). Several systems based in silica NPs 
have been widely applied in biological imaging and ultrasensitive bioassays, including cell 
staining (Santra et al., 2001a), DNA detection (He et al., 2006; Zhao et al., 2003), cell surface 
receptor targeting (Her et al., 2006; Santra et al., 2001a, 2001b, 2004), and ultrasensitive 
detection of pathogens (Zhao et al., 2004). Moreover, these NPs can also be conjugated with 
QDs in a core shell like structure, taking advantage of the capabilities of QDs and taking 
advantage of silica chemistries versatility, while reducing toxicity (Qin et al., 2007). 
The first application of dye-doped silica NPs for TB molecular diagnostics was published by 
Qin and co-workers, where a rapid immunological method combining highly luminescent 
RuBpy-doped silica NPs with indirect immunofluorescence microscopy allowed for 
detection of M. tuberculosis in both mixed bacterial and sputum samples (Qin et al., 2007). 
Later on, this approach was improved by using two-color flow-cytometry and adding SYBR 
Green I to avoid false positives (Qin et al., 2008). Briefly, M. tuberculosis is first recognized by 
the antibody-conjugated RuBpy-doped silica NPs, and then stained with a nucleic acid dye 
SYBR Green I to discriminate bacterial cells from background particles, followed by 
multiparameter determination with flow-cytometry. This way, the population of M. 
tuberculosis dual stained with antibody-conjugated RuBpy-doped silica NPs and SYBR-I 
could be discerned as a distinct population and the false positives caused by aggregates of 
NP-bioconjugates and nonspecific binding of NP-bioconjugates to background debris could 
be decreased dramatically, when compared with the initial one-color approach. Moreover, 
the decrease of false positives also allowed achieving a higher sensitivity for detection of M. 
tuberculosis.  This later dual-color approach allowed for detection of TB in buffer and spiked 
urine, with higher sensitivities than the conventional flow cytometry techniques, 
maintaining the same simplicity, speed and usability.  
3.2 Nano-fabricated devices  
Several biosensors for the determination of short sequences from the M. tuberculosis DNA 
have been described (Buijtels et al., 2008; Csako, 2006; McGlennen, 2001). Wang and co-
workers developed a sensor that relies on the modification of the carbon-paste transducer 
oligonucleotide probe and their hybridization to complementary strands from the M. 
tuberculosis DNA (Wang et al., 1997). Chronopotentiometry was employed as transducer and 
the sensor allowed detection down to nanograms per milliliter of M. tuberculosis DNA. 
Prabhakar et al. used cysteine modified NH2-end peptide nucleic acid probes and 5′-thiol 
end labeled DNA probes immobilized onto BK-7 gold coated glass plates for specific 
detection of M. tuberculosis using SPR (Prabhakar et al., 2008). More recently, Das and co-
workers developed nanostructured zinc oxide films on conducting indium–tin–oxide coated 
glass plate to immobilize a DNA probe and specifically detect M. tuberculosis based on the 
strong electrostatic interactions between ZnO and the complementary target (Das et al., 
2010). The presence of nanostructured ZnO films allowed to increase the electro-active 
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surface area for DNA molecules loading and detect genomic target DNA up to 100 pM, 
which enables the direct detection of pathogens in clinical samples at point of care.  
These nanofabricated sensors have the capability of reducing the costs of the automated 
sensitive detection, making them ideal for point-of-care applications. Moreover, these 
platforms demonstrate the most promising trends in bioanalytical and biochemical methods, 
the fusion of different approaches, methods and technologies into a single platform. 
3.3 Nano-electromechanical devices – nanocantilevers 
Nanocantilevers are one of the most promising nanotechnologies for identification of 
biomolecules capable of providing label-free detection with high sensitivity and specificity 
(Craighead, 2007). These systems can operate either statically, by measuring absolute 
cantilever deflection, or dynamically, by measuring resonance frequency shifts. In the static 
mode, the main parameter measured is the differential surface stress produced when 
molecular adsorption is produced on one side of the cantilever (Fritz et al., 2000). In dynamic 
mode, sensing relies on the observation of the dynamical properties of a resonant cantilever 
(e.g. vibration amplitude, resonance frequency), which has been increasingly applied for 
mass sensing (Craighead, 2007; Waggoner & Craighead, 2007). Sensors based on static 
operation have demonstrated their potential for selective detection of DNA and proteins in 
liquid. Mass sensors based on dynamic mode can potentially achieve sub-femtomolar 
sensitivity (Llic et al., 2005). The ultrahigh mass sensitivity is counterbalanced with a very 
low selectivity due to the device contamination with non-sought molecules and salt debris 
(Varshney et al., 2008). Thus, in practice small bio-molecules, such as proteins or 
oligonucleotides, can be detected at low concentrations. Recent developments merged this 
nanotechnology with AuNPs as sensitizing agents (Wittenberg & Haynes, 2009). These NPs 
act as mass enhancers, allowing detection of biomolecules at the femtomolar level and 
beyond, while maintaining the possibility of performing parallel analyses and working with 
minute sample volumes. Despite these advantages, to our knowledge, nano-
electromechanical systems have not yet been applied to the diagnostics of TB. 
4. Conclusions 
In the last decades we witnessed the development of nanotechnology in isolated fields of 
research, introducing new and revolutionary approaches for molecular detection. Today the 
most promising advances are made at the interface, merging two or more technological 
architectures for new hybrid approaches, circumventing current limitations of each existing 
techniques for biomolecule analysis protocols. Tremendous advancements in the 
development and performance of new technological approaches for the rapid diagnostics of 
TB and prediction of drug resistance have been made in the last few years. The obvious 
advantages of nanodiagnostics based schemes are their ability to provide results within 
hours, with increased sensitivities and specificities at a fraction of a cost when compared to 
conventional microbiological and molecular biology methodologies, such as sputum smear 
microscopy and nucleic acid amplification based techniques. Nevertheless, thus far, only a 
very small number of these new nanodiagnostics platforms have been translated to the 
clinical setting for TB molecular diagnostics. The great efforts put into the development of 
proof-of-concept approaches most of the time lack the connection and the robustness to 
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make an impact in the analytical laboratory and very few techniques are available for direct 
application in respiratory specimens (Lee et al., 2009, 2010). It is expected that in the next 
few years, some of the strategies depicted throughout this short chapter can take their 
rightful place at the front line of fighting TB. 
Future trends in nanodiagnostics will continue through miniaturization of biochip 
technology to the nanoscale range for point-of-care diagnostics with a sample-in answer-out 
approach that hampers user-error, thus enabling their use by non-specialized personnel.  
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